T1	Participants 0 24	Gene variants in CYP2C19
T2	Participants 96 141	bupropion-assisted smoking cessation outcomes
T3	Participants 144 153	Bupropion
T4	Participants 182 192	depression
T5	Participants 208 225	smoking cessation
T6	Participants 248 254	CYP2B6
T7	Participants 317 323	CYP2B6
T8	Participants 355 378	bupropion plasma levels
T9	Participants 492 558	s hydroxybupropion, threohydrobupropion, and erythrohydrobupropion
T10	Participants 667 676	bupropion
T11	Participants 734 741	CYP2C19
T12	Participants 762 788	bupropion pharmacokinetics
T13	Participants 816 837	42 healthy volunteers
T14	Participants 839 848	CYP2C19*2
T15	Participants 980 982	hy
T16	Participants 1088 1098	CYP2C19*2,
T17	Participants 1167 1216	threohydrobupropion and erythrohydrobupropion AUC
T18	Participants 1125 1134	CYP2C19*2
T19	Participants 1244 1259	CYP2B6 genotype
T20	Participants 1298 1314	CYP2C19 variants
T21	Participants 1500 1517	smoking cessation
T22	Participants 1593 1609	hydroxybupropion
T23	Participants 1717 1724	CYP2C19
T24	Participants 1787 1796	bupropion
T25	Participants 1827 1872	threohydrobupropion and erythrohydrobupropion
T26	Participants 1944 1955	bupropion's
T27	Participants 1975 1992	smoking cessation
T28	Participants 1996 2003	smokers
T29	Participants 2069 2078	bupropion
